Medtronic/$MDT
1D1W1MYTD1Y5YMAX
Capital at risk
About Medtronic
One of the largest medical-device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, transcatheter heart valves, stents, surgical robots, spinal fixation devices, neurovascular products, advanced energy, ablation laser therapy, and surgical tools. The company primarily markets its products to healthcare institutions and physicians in the United States, Western Europe, and Japan. Foreign sales account for roughly 50% of the company's total sales.
- Ticker
- $MDT
- Sector
- Health
- Primary listing
- NYSE
- Employees
- 95,000
- Headquarters
- Galway, Ireland
- Website
- www.medtronic.com
Medtronic Metrics
BasicAdvanced
$110B
21.28
$4.06
0.57
$2.85
3.33%
Price and volume
Market cap
$110B
Beta
0.57
52-week high
$106.33
52-week low
$73.31
Average daily volume
12M
Dividend rate
$2.85
Financial strength
Current ratio
2.067
Quick ratio
1.286
Long term debt to equity
0.504
Total debt to equity
0.582
Dividend payout ratio (TTM)
69.78%
Interest coverage (TTM)
10.46%
Profitability
EBITDA (TTM)
10,404
Gross margin (TTM)
65.27%
Net profit margin (TTM)
13.93%
Operating margin (TTM)
20.21%
Effective tax rate (TTM)
20.19%
Revenue per employee (TTM)
$400,000
Management effectiveness
Return on assets (TTM)
5.12%
Return on equity (TTM)
10.65%
Valuation
Price to earnings (TTM)
21.278
Price to revenue (TTM)
2.948
Price to book
2.2
Price to tangible book (TTM)
-33.82
Price to free cash flow (TTM)
18.05
Free cash flow yield (TTM)
5.54%
Free cash flow per share (TTM)
4.786
Dividend yield (TTM)
3.30%
Forward dividend yield
3.33%
Growth
Revenue change (TTM)
9.77%
Earnings per share change (TTM)
12.12%
3-year revenue growth (CAGR)
5.96%
10-year revenue growth (CAGR)
2.71%
3-year earnings per share growth (CAGR)
14.42%
10-year earnings per share growth (CAGR)
4.68%
3-year dividend per share growth (CAGR)
1.44%
10-year dividend per share growth (CAGR)
6.14%
What the Analysts think about Medtronic
Analyst ratings (Buy, Hold, Sell) for Medtronic stock.
Analyst projections of the future price of Medtronic stock.
Bulls say / Bears say
The FDA approved Medtronic’s Onyx 12 embolic system for a type of chronic subdural haematoma, and the company said initial US sales would begin shortly. Its quicker preparation time and new treatment use give the neurovascular portfolio another product-led growth opportunity. (Medtronic)
The FDA classified the Bravo capsule delivery-device recall as Class I, its most serious category; Medtronic had reported 184 serious injuries and no deaths by 10 August. The safety issue brings potential reputation and liability risk. (FDA)
A jury ordered Medtronic to pay $88 million in the first hernia-mesh case to go to trial, one of thousands of claims against the company. Medtronic plans to challenge the verdict, but further cases could add legal costs and uncertainty. (Reuters)
Medtronic’s FY26 adjusted operating margin fell by 100 basis points, while management expected about $250 million of tariff costs in FY27. Those pressures could limit how much of its sales growth converts into profit. (Medtronic, The Motley Fool)
Data summarised monthly by Lightyear AI. Last updated on 1 Oct 2026.
Medtronic Financial Performance
Revenues and expenses
Medtronic Earnings Performance
Company profitability
Upcoming events
Medtronic News
AllArticlesVideos
Funds containing Medtronic
AllEURGBPUSD
Fund name | Fund size | $MDT weighting |
|---|---|---|
iShares S&P 500 Health Care Sector€IUHE | €125M | 1.84% |
SPDR S&P US Dividend Aristocrats€SPYD | €3.3B | 1.77% |
SPDR S&P US Dividend Aristocrats£USDV | £2.8B | 1.77% |
iShares AI Adopters and Applications€AIAA | €169M | 1.58% |
iShares AI Adopters and Applications£AIAA | £145M | 1.58% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.